|
|
|
|
| |
|
|
| Katayama,M.L.H.; Brentani,H.; Abreu,A.P.S.; Barbosa,E.M.; Oliveira,C.T.; Góes,J.C.S.; Brentani,M.M.; Folgueira,M.A.A.K.. |
| In breast cancer patients submitted to neoadjuvant chemotherapy (4 cycles of doxorubicin and cyclophosphamide, AC), expression of groups of three genes (gene trio signatures) could distinguish responsive from non-responsive tumors, as demonstrated by cDNA microarray profiling in a previous study by our group. In the current study, we determined if the expression of the same genes would retain the predictive strength, when analyzed by a more accessible technique (real-time RT-PCR). We evaluated 28 samples already analyzed by cDNA microarray, as a technical validation procedure, and 14 tumors, as an independent biological validation set. All patients received neoadjuvant chemotherapy (4 AC). Among five trio combinations previously identified, defined by nine... |
| Tipo: Info:eu-repo/semantics/other |
Palavras-chave: Breast neoplasms; Discriminant analysis; Doxorubicin; Drug resistance; Neoadjuvant therapy; Reverse transcriptase-polymerase chain reaction. |
| Ano: 2010 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010001200012 |
| |
|
|
|
